Brokerages expect West Pharmaceutical Services, Inc. (NYSE:WST) to announce $415.53 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for West Pharmaceutical Services’ earnings, with the lowest sales estimate coming in at $411.50 million and the highest estimate coming in at $418.00 million. West Pharmaceutical Services reported sales of $382.30 million in the same quarter last year, which indicates a positive year over year growth rate of 8.7%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $415.53 million for the current fiscal year. For the next financial year, analysts anticipate that the company will post sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.14. The business had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.53 EPS.

Several equities research analysts have recently commented on WST shares. Jefferies Group raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price target for the stock from $96.00 to $115.00 in a research note on Friday, September 15th. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Stephens started coverage on West Pharmaceutical Services in a research report on Tuesday, October 3rd. They set an “equal weight” rating and a $99.00 price objective for the company. Bank of America downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research report on Tuesday, October 17th. Finally, Wells Fargo & Company lifted their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $106.00.

Institutional investors have recently modified their holdings of the stock. Acrospire Investment Management LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $113,000. Citigroup Inc. raised its position in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 765 shares during the last quarter. Grandfield & Dodd LLC acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $201,000. Wolverine Trading LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $200,000. Finally, Nomura Holdings Inc. acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $201,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Shares of West Pharmaceutical Services (WST) opened at $99.11 on Friday. The company has a market capitalization of $7,360.00, a P/E ratio of 41.53, a PEG ratio of 2.05 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. West Pharmaceutical Services has a 52 week low of $77.97 and a 52 week high of $103.36.

TRADEMARK VIOLATION NOTICE: “West Pharmaceutical Services, Inc. (WST) Expected to Announce Quarterly Sales of $415.53 Million” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/west-pharmaceutical-services-inc-wst-expected-to-announce-quarterly-sales-of-415-53-million-2/1738453.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.